By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exosome Diagnostics has raised $20 million to further develop and commercialize its exosome-based diagnostics.

The company also said it is creating R&D and service operations in New York, where the company is based, and in Munich.

The financing round was led be NGN Capital and Forbion Capital Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.